Aligos Therapeutics, Inc. ALGS

Rank #2350 · Nasdaq · $0.2B market cap

⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

22.9

P/E

-1.6

P/B

2.22

ROE

-142.5%

Op. Margin

-2469.0%

Debt Ratio

108%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Weak

P/E -1.6x, P/B 2.22x. Ranks in the top 68% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -142.5%. Ranks in the top 96% of the universe.

Safety ★★★☆☆

Average

Debt ratio 108%. Ranks in the top 42% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 41.7% year over year. Ranks in the top 97% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	$0.0B	$-0.1B	$-0.1B	$-0.0B	–	-213
2021	$0.0B	$-0.1B	$-0.1B	$-0.1B	–	-70
2022	$0.0B	$-0.1B	$-0.1B	$0.2B	–	23
2023	$0.0B	$-0.1B	$-0.1B	$0.2B	-1576.2	23
2024	$0.0B	$-0.1B	$-0.1B	$0.1B	-1423.5	57
2025	$0.0B	$-0.1B	$-0.1B	$0.1B	-2469.0	108

← See the full screener